达拉非尼联合曲美替尼治疗BRAFV600E突变低级别和高级别胶质瘤患者(ROAR):一项多中心、开放标签、单臂、2期篮式试验
ROAR篮式试验在13国27中心纳入45例高级别胶质瘤和13例低级别胶质瘤患者,接受达拉非尼150mg每日两次联合曲美替尼2mg每日一次。高级别组客观缓解率33%(95%CI 20-49),低级别组69%(95%CI 39-91)。≥3级不良事件见于31例(53%),安全性与其它适应症一致。
要点
- 高级别胶质瘤组45例中15例(33%;95%CI 20-49)达客观缓解,含3例完全缓解和12例部分缓解。
- 低级别胶质瘤组13例中9例(69%;95%CI 39-91)达客观缓解,含1例完全缓解、6例部分缓解和2例轻微缓解。
- 31例(53%)报告≥3级不良事件,最常见为乏力(5例[9%])和中性粒细胞计数降低(5例[9%])。
核心结论
- 达拉非尼联合曲美替尼在BRAFV600E突变阳性复发或难治性高级别及低级别胶质瘤中显示出有临床意义的活性,安全性与其它适应症一致。
- 作者认为BRAFV600E检测可考虑用于胶质瘤患者的临床实践。
研究设计与样本
- ROAR为正在进行的开放标签、单臂、2期篮式试验,在13个国家27个社区和学术癌症中心开展。
- 高级别胶质瘤队列纳入45例(其中31例为胶质母细胞瘤),低级别胶质瘤队列纳入13例,年龄≥18岁,ECOG体能状态0-2。
- 患者口服达拉非尼150mg每日两次联合曲美替尼2mg每日一次,直至不可接受毒性、疾病进展或死亡。
- 主要终点为可评估意向治疗人群中研究者评估的客观缓解率(高级别胶质瘤为完全缓解+部分缓解;低级别胶质瘤为完全缓解+部分缓解+轻微缓解)。
- 入组时间为2014年4月17日至2018年7月25日,本次结果基于第16次期中分析(数据截止2020年9月14日)。
主要发现
- 高级别胶质瘤队列中位随访12.7个月(IQR 5.4-32.3),45例中15例(33%;95%CI 20-49)达客观缓解,包括3例完全缓解和12例部分缓解。
- 低级别胶质瘤队列中位随访32.2个月(IQR 25.1-47.8),13例中9例(69%;95%CI 39-91)达客观缓解,包括1例完全缓解、6例部分缓解和2例轻微缓解。
- 31例(53%)报告≥3级不良事件,最常见为乏力(5例[9%])、中性粒细胞计数降低(5例[9%])、头痛(3例[5%])和中性粒细胞减少(3例[5%])。
临床怎么用
- 作者认为BRAFV600E检测可考虑用于胶质瘤患者的临床实践。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Effective treatments are needed to improve outcomes for high-grade glioma and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated in adult patients with recurrent or progressive BRAFV600E mutation-positive high-grade glioma and low-grade glioma. METHODS: This study is part of an ongoing open-label, single-arm, phase 2 Rare Oncology Agnostic Research (ROAR) basket trial at 27 community and academic cancer centres in 13 countries (Austria, Belgium, Canada, France, Germany, Italy, Japan, the Netherlands, Norway, South Korea, Spain, Sweden, and the USA). The study enrolled patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0, 1, or 2. Patients with BRAFV600E mutation-positive high-grade glioma and low-grade glioma received dabrafenib 150 mg twice daily plus trametinib 2 mg once daily orally until unacceptable toxicity, disease progression, or death. In the high-grade glioma cohort, patients were required to have measurable disease at baseline using the Response Assessment in Neuro-Oncology high-grade glioma response criteria and have been treated previously with radiotherapy and first-line chemotherapy or concurrent chemoradiotherapy. Patients with low-grade glioma were required to have measurable non-enhancing disease (except pilocytic astrocytoma) at baseline using the Response Assessment in Neuro-Oncology low-grade glioma criteria. The primary endpoint, in the evaluable intention-to-treat population, was investigator-assessed objective response rate (complete response plus partial response for high-grade glioma and complete response plus partial response plus minor response for low-grade glioma). This trial is ongoing, but is closed for enrolment, NCT02034110. FINDINGS: Between April 17, 2014, and July 25, 2018, 45 patients (31 with glioblastoma) were enrolled into the high-grade glioma cohort and 13 patients were enrolled into the low-grade glioma cohort. The results presented here are based on interim analysis 16 (data cutoff Sept 14, 2020). In the high-grade glioma cohort, median follow-up was 12·7 months (IQR 5·4-32·3) and 15 (33%; 95% CI 20-49) of 45 patients had an objective response by investigator assessment, including three complete responses and 12 partial responses. In the low-grade glioma cohort, median follow-up was 32·2 months (IQR 25·1-47·8). Nine (69%; 95% CI 39-91) of 13 patients had an objective response by investigator assessment, including one complete response, six partial responses, and two minor responses. Grade 3 or worse adverse events were reported in 31 (53%) patients, the most common being fatigue (five [9%]), decreased neutrophil count (five [9%]), headache (three [5%]), and neutropenia (three [5%]). INTERPRETATION: Dabrafenib plus trametinib showed clinically meaningful activity in patients with BRAFV600E mutation-positive recurrent or refractory high-grade glioma and low-grade glioma, with a safety profile consistent with that in other indications. BRAFV600E testing could potentially be adopted in clinical practice for patients with glioma. FUNDING: Novartis.
引用
- Wen PY, Stein A, van den Bent M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2021. PMID: 34838156. doi:10.1016/S1470-2045(21)00578-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。